June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Protein Kinase A inhibitor H89 attenuated experimental proliferative vitreoretinopathy
Author Affiliations & Notes
  • Yali Lyu
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Junsheng Fan
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Lian Cui
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Zhongzhu Deng
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Chao Wang
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Mengwen Li
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Nan Yang
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Jieping Zhang
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Juan Wang
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Qingjian Ou
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Lixia Lyu
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Guotong Xu
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, Tongji Eye Institute, Tongji University School of Medicine (TUSM), Shanghai, China
    Department of Regenerative Medicine and Stem Cell Research Center, Tongji University School of Medicine (TUSM), Shanghai, China
  • Footnotes
    Commercial Relationships   Yali Lyu, None; Junsheng Fan, None; Lian Cui, None; Zhongzhu Deng, None; Chao Wang, None; Mengwen Li, None; Nan Yang, None; Jieping Zhang, None; Juan Wang, None; Qingjian Ou, None; Lixia Lyu, None; Guotong Xu, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5971. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Yali Lyu, Junsheng Fan, Lian Cui, Zhongzhu Deng, Chao Wang, Mengwen Li, Nan Yang, Jieping Zhang, Juan Wang, Qingjian Ou, Lixia Lyu, Guotong Xu; Protein Kinase A inhibitor H89 attenuated experimental proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5971.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Proliferative vitreoretinopathy (PVR) is the major cause of failure in surgery for rhegmatogenous retinal detachment . Epithelial-to-mesenchymal transition (EMT) of reitnal pigment epithelium(RPE) mediates the main pathogenesis of PVR. Currently there is no effective treatment available,so this study aimed to explore the role of Protein Kinase A(PKA) inhibitor H89 in experimental PVR and thus develop a novel therapeutic approach for PVR.

Methods : In vivo PVR model was made by intravitreal injection of ARPE19 and Platelet rich plasma (PRP) in SD rats. The rats were divided into 3 groups: PBS , ARPE19 +PRP and ARPE19+PRP+H89 respectively. Electroretinogram (ERG) was recorded at indicated times, EMT related markers were evaluated by immunofluorescence (IF) for dissected eyes. In vitro PVR model was prepared by TGFβ treatment. Q-PCR,Western Blot and IF were performed . Scratch assay, cell migration by trans well assay and PKA kinase activity were also examined.

Results : In vivo PVR model, the intervention of H-89 prevented the decrease of b-wave amplitude of ERG in PVR group. H89 attenuated the formation of epiretinal membrane and downregulated the expression of a-SMA and FN1. In vitro, H89 treatment inhibited EMT related genes expression at both protein and mRNA level in RPE cells. In addition, TGFβ1-induced cell migration and proliferation were blocked by H89 treatment, as shown in scratch assay and transwell experiments. It was also found that TGFβ1 treatment increased PKA activity in dose- and time dependent manner.

Conclusions : This study demonstrated that activation of PKA pathway was involved in PVR, H89 can effectively inhibit the EMT of RPE cells in vivo and in vitro model. These data will provide a novel insight into the pathogenesis of PVR. H89 intervention merits further clinical investigation.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Figure 1.H89 inhibited PVR in vivo. A: Treatment of H-89 can rescue the decrease of the b-wave amplitude(There were 6 eyes for each group). B: Treatment of H89 attenuated the formation of epiretinal membrane and downregulated the expression of a-SMA and FN1.

Figure 1.H89 inhibited PVR in vivo. A: Treatment of H-89 can rescue the decrease of the b-wave amplitude(There were 6 eyes for each group). B: Treatment of H89 attenuated the formation of epiretinal membrane and downregulated the expression of a-SMA and FN1.

 

Figure 2.H89 inhibited PVR in vitro.A-D: H89 treatment inhibited EMT related genes expression at both mRNA and protein level (q-PCR,WB and IF). E-H: H89 treatment bloked TGFβ1 induced cell migration and proliferation (scratch and trans well experiments.) I-L:TGFβ1 increased PKA activity in dose- and time dependent manner.

Figure 2.H89 inhibited PVR in vitro.A-D: H89 treatment inhibited EMT related genes expression at both mRNA and protein level (q-PCR,WB and IF). E-H: H89 treatment bloked TGFβ1 induced cell migration and proliferation (scratch and trans well experiments.) I-L:TGFβ1 increased PKA activity in dose- and time dependent manner.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×